Ipamorelin (Pen)

Description

Ipamorelin research pen — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

This listing is Ipamorelin in pen format (10mg fill) — the same research material as our Ipamorelin vials, supplied in a pre-formatted research pen for laboratories that prefer logged, repeatable handling over loose vials. Ipamorelin is a five-residue synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that Novo Nordisk chemists reported in 1998 as an agonist of the growth hormone secretagogue receptor — the receptor cloned in 1996 and later shown to be ghrelin’s^{[1, 2]}. Its published record is largely rat and swine pharmacology, with one human volunteer pharmacokinetic study and one randomised trial that did not beat placebo^[7]. Laboratory research only; the pen is a handling format, not an instruction.

Full research overview, 27-reference study table & limits of the evidence → Ipamorelin in Canada: research guide

Identity at a glance

Batch documentation: a batch-specific COA for the Ipamorelin pen has not been posted yet — see the COA library. Reports for the vial listings, where posted, are on those pages.

What researchers have looked at

• Hormone selectivity (swine, 1998): GH release comparable to GHRP-6 with no rise in ACTH or cortisol above the GHRH response, and no change in FSH, LH, prolactin or TSH^[1].
• Pharmacokinetics (rat, 1998): five-fold lower clearance than GHRP-6, excretion mainly in urine, 60–80% recovered as intact peptide^[3].
• Skeleton (adult female rats, 1999–2000): dose-dependent increase in tibial longitudinal growth rate over 15 days^[4]; after 12 weeks, higher bone mineral content that vanished once corrected for body-weight gain^[5].
• Body fat (mice, 2001): relative fat mass, leptin and food intake went up, through GH-independent mechanisms — the opposite direction to GH itself^[6].
• Humans (2014): a 117-patient randomised trial in postoperative ileus found no significant difference from placebo on any efficacy endpoint^[7].

These are literature findings about the compound in the models named. They are not properties of this pen, and no benefit is claimed for it.

Storage and handling

• Follow the label: keep the pen cool, dry and out of light, and do not subject it to repeated freeze–thaw.
• Log the batch number and dates of receipt and first use, as with any research material. No protocol or administration information is provided here.

Vial strength: IPAMORELIN 10MG. Other pens are on the peptide pens page; the whole range is on our buy peptides online in Canada page. Canada Post from inside Canada (shipping policy).

Related reading: Ipamorelin vs GHRP-2 vs GHRP-6: Ghrelin-Receptor Agonists Compared

Frequently asked questions

What is the Ipamorelin pen?

The same synthetic Ipamorelin supplied in a pre-formatted research pen rather than a loose vial, for laboratories that want repeatable, logged handling. It is a research format only; no administration guidance of any kind is given.

Is there a batch report for the Ipamorelin pen?

Not yet. No batch-specific report for the pen is posted in the COA library. The page will state the report when one exists.

Is the Ipamorelin pen for human use?

No. The pen is supplied for laboratory research only and is not for human or animal use. No dosing, administration or protocol information is provided.

References

1. Raun K, Hansen BS et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PMID 9849822
2. Howard AD, Feighner SD et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. PMID 8688086
3. Johansen PB, Hansen KT et al. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. PMID 9879640
4. Johansen PB, Nowak J et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. PMID 10373343
5. Svensson J, Lall S et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. PMID 10828840
6. Lall S, Tung LY et al. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. PMID 11162489
7. Beck DE, Sweeney WB et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PMID 25331030
8. Gajda PM, Holm NB et al. (2019). Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. PMID 30136411

For laboratory research use only. Not for human or animal consumption. This description identifies the material and summarises published preclinical and clinical literature on the compound; it makes no claim of efficacy or safety for the material sold.